Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MELK | Q14680 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.33 |
| ▸ | MERTK | Q12866 | 2/20 | 0.33 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076725 | 0.89 | CNR1 (0.32) | — | |
| SCHEMBL2076372 | 0.88 | BCDIN3D (0.33) | — | |
| SCHEMBL2077740 | 0.86 | RAB9A (0.39) | RAB9AMELKLCKMAPK14MAPT | |
| SCHEMBL2076349 | 0.85 | EGFR (0.39) | RAB9AMAPTLMNATYRO3MERTK | |
| SCHEMBL2078499 | 0.82 | EGFR (0.38) | MAPTMEN1KMT2ACHEK1KDM4E | |
| SCHEMBL2078312 | 0.80 | TLR8 (0.35) | — | |
| SCHEMBL2077542 | 0.80 | MAPT (0.37) | RAB9AMAPTLMNAMEN1KMT2A | |
| SCHEMBL2076726 | 0.80 | MEN1 (0.37) | RAB9AMAPTLMNAMEN1KMT2A | |
| SCHEMBL2078614 | 0.78 | EGFR (0.37) | MAPTLMNACHEK1POLBKDM4E | |
| SCHEMBL12428159 | 0.78 | CHEK1 (0.35) | RAB9AMAPTCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024360-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON INC (US) | 2013-04-03 | — | — | EP | claimed |
| US-7851468-B2 | Substituted pyrazolo[3,4-d]pyrimidines | CEPHALON, INC. (US) | 2010-12-14 | — | — | US | claimed |
| EP-2024360-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON INC (US) | 2013-04-03 | — | — | EP | disclosed |
| EP-2024360-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON INC (US) | 2013-04-03 | — | — | EP | disclosed |
| US-8354414-B2 | Substituted bicyclic pyrimidines | CEPHALON, INC (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354414-B2 | Substituted bicyclic pyrimidines | CEPHALON, INC (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2351751-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2351751-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | CEPHALON, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | CEPHALON, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-7851468-B2 | Substituted pyrazolo[3,4-d]pyrimidines | CEPHALON, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851468-B2 | Substituted pyrazolo[3,4-d]pyrimidines | CEPHALON, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2024360-A2 | SUBSTITUTED PYRAZOLOPYRIMIDINES | Cephalon, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008063232-A2 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063232-A2 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | DPYD, P2RX5, P2RX7 | RAB9A 3405/4885MELK 3027/4885LCK 2447/4885 |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | DPYD, P2RX5, P2RX6 | RAB9A 3082/4885MELK 3393/4885LCK 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.